Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercializationHOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluat ...

分组1 - Plus Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.03, compared to a loss of $0.67 per share a year ago, indicating an earnings surprise of +100.00% [1] - The company posted revenues of $1.37 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.02%, although this represents a decline from year-ago revenues of $1.41 million [2] - Plus shares have declined approximately 39.9% since the beginning of the year, contrasting with the S&P 500's decline of 1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $1.15 million, and for the current fiscal year, it is -$0.16 on revenues of $5.16 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 35% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Core Insights - The article discusses the recent financial performance of a leading technology company, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $50 billion for the last quarter, representing a 20% increase year-over-year [1] - Net income reached $10 billion, which is a 25% increase compared to the same quarter last year [1] - The earnings per share (EPS) rose to $5, up from $4 in the previous year, indicating strong profitability [1] Market Position - The company has strengthened its market position, capturing a larger share in the cloud computing sector, which is projected to grow at a rate of 15% annually [1] - The company’s investment in research and development has increased by 30%, totaling $5 billion, to enhance its product offerings and maintain competitive advantage [1] Future Outlook - Analysts predict continued growth for the company, with expected revenue growth of 15% for the upcoming fiscal year [1] - The company plans to expand its operations into emerging markets, which could contribute an additional $2 billion in revenue [1]

Financial Performance and Condition - For the year ended December 31, 2025, the company incurred net losses of $22.4 million and net cash used in operating activities was $20.8 million, with an accumulated deficit of $515.9 million[179]. - The company expects to continue incurring net losses and negative cash flow from operating activities for at least the next twelve months, primarily due to increased expenses associated with research and development and clinical trial-related activities[179]. - As of December 31, 2025, the company had approximately $13.1 million in cash and cash equivalents, restricted cash, and short-term investments, raising substantial doubt about its ability to continue as a going concern[182]. - The company has a history of generating losses and negative cash flows from operations, and its financial statements have been prepared under the assumption of continuing as a going concern for the next twelve months[183]. - The company requires additional funding to develop its product candidates and conduct future operations, and it may pursue various financing options, including debt and equity offerings[197]. Compliance and Regulatory Issues - The company is subject to compliance with Nasdaq's Minimum Stockholders' Equity Requirement of at least $2.5 million, and it received additional time until March 4, 2025, to regain compliance[188]. - The company was notified on May 16, 2025, that it no longer complied with the Minimum Bid Requirement, with an initial compliance period until November 12, 2025, to regain compliance[189]. - If the company fails to regain compliance with Nasdaq's listing requirements, it could face significant material adverse consequences, including a decline in the market price of its common stock[192]. - The company is subject to the Sarbanes-Oxley Act and must maintain effective internal controls over financial reporting, with potential implications for timely and accurate financial statements[206]. - The company faces ongoing regulatory obligations that may result in significant expenses and could harm business if compliance is not maintained[275]. Product Development and Market Strategy - The company has established a scalable testing laboratory in Houston, TX, and has obtained state licensure for 49 of 50 US states by January 2026, with plans for New York by 2027[217]. - The company acquired the CNSide Portfolio in 2024 and is executing a commercial market access strategy, including agreements with UnitedHealthcare and Humana[217]. - The company is focused on developing its nanomedicine platform, specifically rhenium (186Re) obisbemeda and 188RNL-BAM, but faces significant regulatory and development risks[210]. - The company has limited product candidates in development, and its business heavily relies on their successful commercialization and regulatory approval[225]. - The company emphasizes the importance of strategic partnerships for commercialization, as it lacks the resources to independently develop and market its therapeutic offerings[223]. Clinical Trials and Regulatory Approval - Clinical trials for product candidates are lengthy and expensive, with uncertain outcomes that may lead to delays or failures in development[246]. - The company relies on third-party service providers for clinical trials, and any failure by these providers could adversely affect trial outcomes[251]. - Regulatory authorities may suspend clinical trials for various reasons, which could delay the commercialization of product candidates[252]. - The company may incur additional costs or experience delays in clinical trials due to unforeseen circumstances, impacting its ability to generate revenues[253]. - Any significant adverse events during clinical trials could lead to challenges in obtaining regulatory approval and market acceptance, adversely affecting financial position[266]. Intellectual Property and Competition - The company relies on the protection of its intellectual property, including patents and trade secrets, for its platform technology and product candidates[343]. - The future protection of proprietary rights is uncertain due to recent changes in patent laws and interpretations, which may affect the ability to obtain and maintain patents[345]. - The company may face challenges in obtaining patent term extensions for product candidates, which could materially harm its business[348]. - The company faces competition in acquiring product candidates or technologies, which may hinder growth if suitable opportunities are not identified[320]. - The company faces significant competition from established drugs and therapies, which may impact the commercial viability of its product candidates[239]. Financial Risks and Market Conditions - The market price of the company's common stock may be volatile, influenced by operating results, clinical trial outcomes, and changes in market conditions[365]. - The company has the authority to issue up to 2 billion shares of common stock and 5 million shares of preferred stock, which could lead to substantial dilution for existing shareholders[362]. - Significant additional capital will be needed for operations, including product development and clinical trials, which may require selling equity securities[363]. - The company may face claims regarding the wrongful use of trade secrets by employees who previously worked for competitors, potentially leading to costly litigation[353]. - The company may experience extreme price and volume fluctuations in its common stock due to loss of investor confidence[367].

Financial Performance - The net loss for the year ending December 31, 2025, was $22.4 million, or $(0.29) per basic share, compared to a net loss of $13.0 million, or $(1.95) per basic share, for the year ending December 31, 2024[7]. - The total operating loss for the year ending December 31, 2025, was $15.3 million, an increase from $14.7 million for the year ending December 31, 2024, primarily due to the expansion of the CNSide operations team[6]. - The net loss increased significantly to $22,386 million in 2025 from $12,978 million in 2024, reflecting an increase of approximately 72%[21]. - The company reported a net loss per share of $0.29 for 2025, an improvement from a net loss per share of $1.95 in 2024[21]. Revenue and Expenses - The company recognized $5.2 million in grant revenue for the year ending December 31, 2025, compared to $5.8 million for the year ending December 31, 2024[6]. - Grant revenue decreased to $5,213 million in 2025 from $5,824 million in 2024, representing a decline of approximately 10.5%[21]. - Total operating expenses remained relatively stable at $20,511 million in 2025 compared to $20,519 million in 2024, showing a slight decrease of 0.04%[21]. - The company incurred research and development expenses of $8,379 million in 2025, down from $10,580 million in 2024, a decrease of about 20.8%[21]. Cash Position - The cash and investments balance was $13.1 million on December 31, 2025, compared to $3.6 million on December 31, 2024, indicating a significant increase in liquidity[6]. - Cash and cash equivalents at the end of the period increased to $8,758 million in 2025 from $76 million in 2024, marking a substantial increase[23]. - Net cash used in operating activities rose to $20,775 million in 2025, compared to $10,554 million in 2024, indicating an increase of about 96%[23]. - Financing activities generated a net cash inflow of $30,311 million in 2025, compared to $6,187 million in 2024, representing an increase of approximately 388%[23]. Future Outlook - The company expects research and development expenditures to increase in 2026 due to costs associated with the ReSPECT-LM clinical trial and manufacturing scale-up for REYOBIQ[8]. - The company anticipates general and administrative expenditures to increase in 2026 as it expands the CNSide commercial operations team, aiming for breakeven by 2027[9]. - The company plans to expand U.S. commercial payer coverage to over 150 million covered lives and secure a Medicare coverage pathway[12]. - The company aims to achieve over 1,250 annualized test orders and launch additional CSF tumor characterization assays to expand the CNSide platform[12]. Shareholder Information - The weighted average number of shares outstanding for basic common stock increased significantly to 77,804,612 in 2025 from 6,640,251 in 2024[21]. - Interest income decreased to $116 million in 2025 from $273 million in 2024, reflecting a decline of approximately 57.5%[21].

Core Insights - Plus Therapeutics, Inc. is focused on developing precision diagnostics and radiopharmaceuticals for CNS cancers, with significant financial results and business highlights reported for Q4 2025 and the full year [1] Corporate Highlights - The company completed an upsized public offering generating $15 million in gross proceeds, extending its cash runway to support CNSide commercialization and two ongoing Phase 2 clinical programs [2] - The company secured an American Medical Association Category III CPT reimbursement code for REYOBIQ, enhancing market access for its therapy in recurrent glioblastoma and pediatric brain cancer [7] - CNSide laboratory licensing has expanded to 49 of 50 U.S. states, allowing access to the CNSide Tumor Cell Enumeration test for approximately 95% of the U.S. population [7] - The company recognized $5.2 million in grant revenue for 2025, compared to $5.8 million in 2024, primarily from CPRIT for REYOBIQ development [7] Financial Results - The company's cash and investments balance was $13.1 million on December 31, 2025, up from $3.6 million on December 31, 2024 [7] - Total operating loss for 2025 was $15.3 million, compared to $14.7 million in 2024, attributed to the expansion of the CNSide operations team [7] - Net loss for 2025 was $22.4 million, or $(0.29) per basic share, compared to a net loss of $13.0 million, or $(1.95) per basic share, in 2024 [7] Development and Clinical Programs - REYOBIQ is being evaluated for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in ongoing clinical trials [12] - The company anticipates increased R&D expenditures in 2026 due to costs associated with the ReSPECT-LM clinical trial and manufacturing scale-up for REYOBIQ [9] - The company aims for CNSide Diagnostics to breakeven by 2027, with expected increases in general and administrative expenditures in 2026 [10] Future Milestones - The company plans to define the optimal dose for REYOBIQ in the ReSPECT-LM Phase 2 trial, with data expected in Q3 2026 [15] - Enrollment in the ReSPECT-GBM Phase 2 trial is expected to be completed, with data anticipated in Q4 2026 [15] - The company aims to expand U.S. commercial payer coverage to over 150 million covered lives and achieve more than 1,250 annualized test orders [16]

Core Insights - Plus Therapeutics has received approval for a new Category III CPT code from the American Medical Association to track the utilization of convection-enhanced delivery (CED) for REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer, marking a significant step towards market access and commercialization [1][2] Group 1: REYOBIQ Therapy - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [3] - The therapy is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions, including a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [3] Group 2: Market Access and Utilization Tracking - The approved Category III CPT code, X566T, will facilitate the tracking of CED procedures for REYOBIQ, aiding in the evaluation of its clinical use and supporting future reimbursement and coverage decisions [2] - The new CPT code will be published on July 1, 2026, and will take effect for reporting on January 1, 2027, which is expected to enhance the adoption of REYOBIQ in clinical settings [2] Group 3: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging CNS cancers, aiming to improve clinical outcomes through innovative treatment approaches [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - The company provided a business update regarding its REYOBIQ clinical program and CNSide U.S. commercialization [2][3] Company Developments - The latest corporate presentation was filed with the SEC in an 8-K filing and is available on the company's website [3] - The conference call included participation from the CEO and CFO, indicating a focus on future performance and operational results [3] Communication and Transparency - The company emphasized the availability of its press release and corporate presentation on its website for investor access [2][3]

Summary of Plus Therapeutics Conference Call - January 22, 2026 Company Overview - **Company**: Plus Therapeutics (NasdaqCM:PSTV) - **Focus**: Development of CNSide and RIOVA clinical programs Key Points Financial Update - **Recent Offering**: Completed a $15 million oversubscribed financial offering on January 14, 2026, which extends the company's runway through 2027 [4] - **Use of Funds**: Funds will be used to expand CNSide investments to achieve break-even by 2027 and to complete ongoing phase II RIOVA clinical trials [4] RIOVA Clinical Program - **FDA Interaction**: Positive feedback from a Type B meeting with the FDA in November 2025, which will expedite RIOVA clinical development timelines [5] - **Trial Design**: Agreement on a randomized pivotal trial design focusing on neurologic condition improvements, patient-reported outcomes, and overall survival as key endpoints [6] - **2026 Goals**: Aim to identify optimal RIOVA dosing regimes and expand into a 12-patient dose expansion arm for additional safety and efficacy data [7] - **Enrollment Progress**: On track to complete phase II enrollment for recurrent glioblastoma (GBM) with data expected in Q4 2026 [7] CNSide Commercialization - **Licensure**: Achieved state licensure in 49 of 50 U.S. states, with agreements covering 67 million lives through partnerships with UnitedHealthcare and Humana [8] - **2026 Focus**: Targeting over 150 million covered lives through additional payer agreements, obtaining Medicare and Medicaid coverage, and ramping up testing utilization to reestablish previous commercial run rates of 1,250 tests per year [8] - **Physician Engagement**: Goal to establish a base of 50 unique ordering physicians, with a long-term target of reaching 200 [28] Operational Insights - **Testing Goals**: Aiming for 1,250 tests per year as a minimum goal, which is expected to cover only a quarter of the path to profitability; a target of 5,000 tests is needed for full profitability [31] - **Cost Efficiency**: Significant opportunities for automation and cost reductions have been identified since acquiring testing assets from the previous company [32] Strategic Outlook - **Market Positioning**: Emphasis on improving diagnostic capabilities with CNSide and bringing the RIOVA drug to market to address unmet medical needs in CNS cancers [35] - **Future Announcements**: Management is optimistic about upcoming announcements that could positively impact stock performance, with no immediate plans for a reverse stock split [19] Risk Factors - **Forward-Looking Statements**: The company has cautioned that actual results may differ from expectations due to various risks outlined in their SEC filings [3] Additional Considerations - **Payer Dynamics**: The company is working on obtaining PLA and DEX Z-Codes for Medicare and Medicaid coverage, which are crucial for expanding market access [26] - **Patient Demographics**: Noted that the demographic for CNSide testing skews younger, with a 60/40 split between private payers and Medicare [27] This summary encapsulates the critical updates and strategic direction of Plus Therapeutics as discussed in the conference call, highlighting both opportunities and challenges ahead.